Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma

M Gurnell, C Domingo, K F Rabe, A Menzies-Gow, D Price, G Brusselle, M E Wechsler, C Xia, N Pandit-Abid, R Gall, J A Jacob-Nara, P J Rowe, Y Deniz, S Siddiqui

Research output: Contribution to journalAbstractpeer-review

Abstract

Background Dupilumab (DPL), a fully human anti-IL-4Rα mAb, blocks interleukin-4/13, key and central drivers of type 2 inflammation. TRAVERSE (NCT02134028), a single-arm, open-label extension study, evaluated the long-term safety and efficacy of DPL 300mg q2w for up to 96 weeks in patients (pts) from VENTURE.Aim To assess DPL efficacy in TRAVERSE pts with severe OCS-dependent asthma by OCS dose at parent study baseline (PSBL; VENTURE).Methods Pts from TRAVERSE were analyzed as DPL/DPL or placebo (PBO)/DPL group and stratified by OCS dose (≤10/>10mg/day at PSBL). % reduction in OCS dose and change in pre-BD FEV1 from PSBL at TRAVERSE Weeks (Wks) 0/96; % of pts achieving 0, <5, or <10mg/day OCS; AER during VENTURE and TRAVERSE were assessed.Results 187 pts from TRAVERSE were analyzed. The daily-dose % reductions observed in VENTURE continued during TRAVERSE in DPL/DPL pts (Wk96: ≤10mg/day: −89%, >10mg/day: −83%) and PBO/DPL pts (Wk96: ≤10mg/day: −70%, >10mg/day: −76%). The % pts achieving 0, <5, or <10mg/day OCS continued to improve throughout TRAVERSE regardless of OCS dose at PSBL. Also, AER was lower in TRAVERSE (range: 0.284–0.599) vs VENTURE (0.463–1.587), and pre-BD FEV1 continued to improve in all subgroups (Table).Conclusion OCS dose reductions were sustained, and improvements in AER and lung function continued during TRAVERSE.FootnotesCite this article as Eur Respir J 2022; 60: Suppl. 66, 3620.This article was presented at the 2022 ERS International Congress, in session “-”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
Original languageEnglish
Article number3620
JournalEuropean Respiratory Journal
Volume60
Issue numberSuppl. 66
DOIs
Publication statusPublished - 4 Sep 2022
EventEuropean Respiratory Society (ERS) International Congress. - FIRA Barcelona Gran Via Congress Centre, Barcelona, Spain
Duration: 4 Sep 20226 Sep 2022
https://www.ersnet.org/congress-and-events/congress/

Fingerprint

Dive into the research topics of 'Dupilumab reduces OCS use and improves lung function in patients with severe OCS-dependent asthma'. Together they form a unique fingerprint.

Cite this